Four drugs pushed to May meet

Posted 11 February 2025 AM

A new National Immunisation Program (NIP) listing submission and three sub-committee report DUSC analyses originally scheduled for the PBAC’s controversial March meeting will now be considered at a later meeting in May, an update to both meeting agendas shows.

This includes Sanofi’s resubmission seeking listing of Beyfortus on the NIP for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season; and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

To see the whole article, please login